Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level-Reference-Cited by-同舟云学术

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level

Published:2003-09-22 Issue:2 Volume:198 Page:259-268
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J. Cell. Physiol.

Author:

Campiglio Manuela,Locatelli Alberta,Olgiati Clelia,Normanno Nicola,Somenzi Giulia,Viganò Lucia,Fumagalli Marzia,Ménard Sylvie,Gianni Luca

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Reference45 articles.

1. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition;Albanell;J Clin Oncol,2002

2. New technologies in epidermal growth factor receptor-targeted cancer therapy;Baselga;Signal,2002

3. ZD1839 (‘Iressa’) as an anticancer agent;Baselga;Drugs,2000

4. Characteristics of EGFR family-mediated HRG signals in human ovarian cancer;Campiglio;J Cell Biochem,1999

5. p185 HER2/neu epitope mapping with murine monoclonal antibodies;Centis;Hybridoma,1992

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer;Frontiers in Physiology;2024-03-27

2. Recent trends in the design and delivery strategies of ruthenium complexes for breast cancer therapy;Dalton Transactions;2024

3. Busting the Breast Cancer with AstraZeneca’s Gefitinib;Advances in Pharmacological and Pharmaceutical Sciences;2023-12-04

4. Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy;Cells;2023-04-14

5. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer;BMC Cancer;2021-06-01